Treace Medical Concepts (TMCI) 2024 Truist Securities MedTech Conference summary
Event summary combining transcript, slides, and related documents.
2024 Truist Securities MedTech Conference summary
3 Feb, 2026Market evolution and growth opportunities
Lapiplasty expanded Lapidus-type procedures from 15% to 30% of the U.S. bunion surgery market over several years.
Minimally invasive osteotomies now account for about 10% of all bunion surgeries, with 15% penetration in the osteotomy segment.
The company is preparing to launch two minimally invasive osteotomy platforms by late 2024, aiming for broader market coverage in 2025.
These new platforms target the 70% of procedures currently outside the company's portfolio, representing significant growth potential.
The market is experiencing increased competition, with more companies introducing Lapiplasty-like and MIS osteotomy products.
Product innovation and differentiation
The new minimally invasive osteotomy systems are designed to be more reproducible and easier to use, reducing the current 40-50 case learning curve.
Two platforms are being developed to address different surgeon philosophies and implant fixation preferences.
The company’s approach is to offer both a market-leading Lapidus solution and a differentiated MIS osteotomy, appealing to a wider surgeon base.
SpeedPlate, a new fixation option, has driven surgeon engagement and is used across existing procedures.
The company’s innovation strategy has been in place for years, with early IP filings covering rotational osteotomies.
Competitive landscape and strategic response
The market has shifted with the rapid introduction of competing Lapiplasty-like and MIS osteotomy products.
Surgeons are testing alternative products, changing the mix of procedures and impacting volume trends.
The company continues to add new active surgeons, but the frequency of Lapiplasty use per surgeon has shifted.
The company is responding by expanding its product suite and targeting previously untapped surgeon segments.
Guidance was revised after observing slower base volume in March and April, with analytics supporting the new outlook.
Latest events from Treace Medical Concepts
- 2026 revenue is guided flat to -6%, with Q4 growth expected from new product launches.TMCI
Q4 20258 Apr 2026 - 2026 proxy covers director elections, say-on-pay, auditor ratification, and key governance updates.TMCI
Proxy filing6 Apr 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor ratification.TMCI
Proxy filing6 Apr 2026 - Q3 revenue up 11% to $45.1M; stable margins and new product launches drive growth.TMCI
Q3 20243 Feb 2026 - Q2 revenue up 6% to $44.5M; net loss widens, but 2024 growth and margin outlook reaffirmed.TMCI
Q2 20242 Feb 2026 - New MIS products and reimbursement changes set to drive growth and profitability in 2025.TMCI
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - New product launches and operational leverage set the stage for accelerated growth in 2025.TMCI
UBS Global Healthcare Conference 202414 Jan 2026 - 3D bunion solutions, MIS innovation, and strong adoption drive growth and profitability.TMCI
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Momentum builds for 2025 with new technologies, strong Q4, and favorable reimbursement shifts.TMCI
Stifel 2024 Healthcare Conference13 Jan 2026